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Abstract
Metaplastic breast carcinomas (MBCs) are rare malignancies usually with poor prognosis. We report a case of an 18-year-old
African female patient who presented with a 34-cm tumor on the right breast. Biopsy showed an extensively necrotic MBC
negative for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (triple negative).
A modiﬁed right radical mastectomy was performed, followed by adjuvant chemotherapy. Histology conﬁrmed a widely
necrotic undifferentiatedmalignant tumor, with strong and diffuse expression of vimentin and B-cell lymphoma 2, focal high-
molecular-weight keratins and focal CD34 expression; Ki67 was >90%. There was no skin, deep margin or lymph node
involvement. Sixmonths after surgery, the patient showed a 9 × 7 cmnodule adjacent to the suture and adherent to the anterior
chestwall. The tumorwas considered unresectable and the patient evolvedwith rapid systemic deterioration. The patient had a
progression-free survival of 6 months and overall survival of 9 months.
INTRODUCTION
Metaplastic breast carcinoma (MBC) is a rare aggressive breast
malignancy with poor prognosis [1]. There are no speciﬁc recom-
mendations for MBC management, the standard regimen being
surgery combined with adjuvant therapy, although there is evi-
dence to suggest that MBCs have lower response rates to conven-
tional adjuvant chemotherapy and aworse clinical outcome than
other forms of breast cancers negative for estrogen receptor, pro-
gesterone receptor and human epidermal growth factor receptor 2
(triple negative) [2]. In younger women, breast cancer is asso-
ciated with even worse outcomes [3]. We report a case of an
18-year-old African female patient with MBC, whowas subjected
to the standard of care, but had a progression-free survival (PFS)
of 6 months and an overall survival (OS) of 9 months, thus sup-
porting the poor prognosis of MBC in young women.
CASE REPORT
An 18-year-old African female patient with no relevant past or
family history was admitted at our hospital due to a 34-cm
tumor on the right breast (Fig. 1). The patient, from Cape Verde,
delayed her appointment with a doctor because she could not af-
ford to miss a day at work. When she ﬁnally went to the doctor,
due to rapid growth of the mass, the tumor was extremely large,
and she was immediately evacuated to Portugal. Biopsy showed
an extensively necrotic MBC, triple negative, with Ki67 >90%.
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Thorax, abdomen and pelvic CT showed axillary lymph node in-
volvement, without other secondary foci. Breast MRI showed
probable muscle inﬁltration (Fig. 2). A multidisciplinary team
decided that a modiﬁed right radical mastectomy should be per-
formed (Fig. 3).
Pathology conﬁrmed a widely necrotic tumor with ∼3500 g
and 34 cm, replacing thewhole breast. Histology showed atypical
spindle and some epitheliod cells, with high nuclear pleomorph-
ism, organized in long fascicles with an interwoven pattern and
in a hemangiopericytoid fashion (Fig. 4A and B); themitotic index
was high, with >20 mitosis/10 high-power ﬁelds. There was focal
expression of high-molecular-weight keratins CK903 and AE1/3
(Fig. 4C), and CD34; Ki67 was >90%. Neoplastic cells strongly
and diffusely expressed vimentin (Fig. 4D) and B-cell lymphoma 2.
The tumor was triple negative and also negative for HMB45,
desmin and actin. Skin and deep margin showed no evidence
of neoplasia. None of the 12 isolated lymph nodes showed
tumor invasion (pT3N0). Based on the unequivocal expression of
high-molecular-weight keratins [2], a diagnosis of metaplastic
spindle cell carcinoma was rendered.
The patient underwent adjuvant therapy with four cycles of
doxorubicin and cyclophosphamide. Six months after surgery,
the patient showed a hard and painful nodule adjacent to the
suture and adherent to the chest wall. Ultrasound conﬁrmed a
heterogeneousmulticystic nodule of 9 × 7 cm (Fig. 5). Chest CT re-
vealed right pleural effusion, pleural thickening and consolida-
tion of the adjacent parenchyma. Cytological analysis raised a
suspicion for the presence of malignant cells. Pleural biopsy
was negative for malignancy.
Given the chest wall involvement, the tumor was considered
unresectable and the patient evolved with rapid systemic deteri-
oration and multiple organ failure. PFS was 6 months and OS 9
months.
DISCUSSION
Young women are more likely to develop more aggressive sub-
types of breast cancer with poor prognosis, probably due to mul-
tiple factors, including unfavorable disease biology, delay in
diagnosis and age [3]. On the other hand, MBCs are aggressive re-
gardless of age, usually characterized by rapid progression, need-
ing immediate surgical treatment and en bloc resection. MBCs
account for 0.2–5% of all invasive breast cancers [2], which usual-
ly present as high-grade neoplasms with a large tumor size, less
likely nodal involvement, triple negative, poorly differentiated or
undifferentiated [1, 4, 5] and high Ki67 [6]. Our patient presented
with these characteristics, but was much younger than the re-
ported mean age of 61–63 years [1, 4, 6]. Also, the tumor was
much larger than the reported range of 3.4–13 cm [7, 8].
Although with the use of neoadjuvant therapy for downsta-
ging and downsizing, together with currently available oncoplas-
tic techniques, it is possible to perform conservative breast
oncologic surgery in cases previously treated with radical mast-
ectomy, our ﬁrst surgical option was a modiﬁed right radical
mastectomy given the exceptionally large tumor, followed by ad-
juvant chemotherapy. The use of adjuvant therapy has been the
subject of some debate [1, 4, 6–8]. In our case, adjuvant hormonal
therapy was not an option given the tumor was triple negative.
Since there is no standard treatment regimen speciﬁc for MBC,
we followed the clinical practice guidelines for invasive breast
adenocarcinoma [8], and adjuvant chemotherapy was decided
by our breast cancer multidisciplinary group, given it is used
more often for patientswithMBC [4]. Also, its use in breast cancer
is based on disease stage, not histologic subtype [1], as the prog-
nostic value of histological grading in MBCs is uncertain [2].
Figure 2: MRI T1f study after paramagnetic contrast showing a large mass
occupying the entire right breast with extensive central necrosis.
Figure 3: Surgical specimen.Figure 1: Tumor presentation before surgery.
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Owing to several clinical complications arising during the CT
cycles, relapse and deterioration of the patient’s general health
status, adjuvant radiotherapy could not be offered.
Despite the aggressive treatment, our patient relapsed 6
months after surgery and had an OS of 9 months. PFS and OS of
our patient were much lower than in other studies [1, 5, 8]. This
dismal scenario was not surprising given the tumor presentation
at hospital admittance and the patient’s age and ethnicity.
Not only breast cancer in young women has been associated
with more aggressive, poorly differentiated, estrogen receptor
(ER) negative tumors, but also African-American women have
an increased risk of breast cancer at younger ages and are more
likely to have higher grade, ER-negative cancers [3].
Presently, there are no validated prognosticmarkers formeta-
plastic carcinomas [2]. It is of paramount importance to rapidly
identify these tumors and treat them aggressively, which can
only be achieved with a multidisciplinary approach. The case
we report did not have a good outcome, for a number of reasons.
Although MBC is rare, there are still a signiﬁcant number of pa-
tients who, due to limited access to primary health care, present
with very advanced tumors at hospital admittance, and there is a
need to know how to manage these patients, in order to achieve
the best possible outcome.
The procedures followed were in accordance with the ethical
standards of the Helsinki Declaration of theWorld Medical Asso-
ciation. The patient’s written consent was obtained. The work
has been approved by the Hospital Professor Doutor Fernando
da Fonseca ethical committee.
Figure 4: (A) Spindle cell proliferation with a hemangiopericitoid growth pattern (×4). (B) Nuclear pleomorphism and numerous mitoses (×10). (C) Focal expression of
CK903, revealing epithelial differentiation (×10). (D) Strong and diffuse expression of vimentin (×10).
Figure 5: Ultrasound of the mastectomy bed showing a hypoechoic solid mass in
subpectoral topography with signs of muscle invasion.
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